Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacokinetic Evaluations of Ixekizumab Following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients With Moderate-to-Severe Plaque Psoriasis
Brief Summary: The purpose of this study is to evaluate the serum concentration of ixekizumab after administration using either prefilled syringe or auto-injector in participants with moderate to severe plaque psoriasis. Treatment period is followed by 40 weeks optional safety extension.


Options:
A: Arm Label: Cohort A: INCB018424 Ruxolitinib 0.5%; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib phosphate cream, Drug: Placebo cream | Arm Label: Cohort B: INCB018424 Ruxolitinib 1.0%; Type: EXPERIMENTAL; Interventions: Drug: Placebo cream, Drug: Ruxolitinib phosphate cream | Arm Label: Cohort C: INCB018424 Ruxolitinib 1.5%; Type: EXPERIMENTAL; Interventions: Drug: Placebo cream, Drug: Ruxolitinib phosphate cream | Arm Label: Cohort D: 18424 Ruxolitinib vs Dovonex® calcipotriene; Type: EXPERIMENTAL; Interventions: Drug: Dovonex® calcipotriene 0.005% | Arm Label: Cohort E: 18424 Ruxolitinib vs Diprolene® AF betamethasone diproprionate; Type: EXPERIMENTAL; Interventions: Drug: Diprolene® AF betamethasone dipropionate 0.05% cream. | Intervention Type: DRUG; Name: Ruxolitinib phosphate cream; Assigned to Arm(s): Cohort A: INCB018424 Ruxolitinib 0.5% | Intervention Type: DRUG; Name: Dovonex® calcipotriene 0.005%; Assigned to Arm(s): Cohort D: 18424 Ruxolitinib vs Dovonex® calcipotriene | Intervention Type: DRUG; Name: Diprolene® AF betamethasone dipropionate 0.05% cream.; Assigned to Arm(s): Cohort E: 18424 Ruxolitinib vs Diprolene® AF betamethasone diproprionate | Intervention Type: DRUG; Name: Placebo cream; Assigned to Arm(s): Cohort A: INCB018424 Ruxolitinib 0.5%, Cohort B: INCB018424 Ruxolitinib 1.0%, Cohort C: INCB018424 Ruxolitinib 1.5% | Intervention Type: DRUG; Name: Ruxolitinib phosphate cream; Assigned to Arm(s): Cohort B: INCB018424 Ruxolitinib 1.0% | Intervention Type: DRUG; Name: Ruxolitinib phosphate cream; Assigned to Arm(s): Cohort C: INCB018424 Ruxolitinib 1.5%
B: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Fumaric Acid Esters; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fumaric Acid Esters, Drug: Ixekizumab | Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Ixekizumab | Intervention Type: DRUG; Name: Fumaric Acid Esters; Assigned to Arm(s): Fumaric Acid Esters | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Fumaric Acid Esters, Ixekizumab, Methotrexate
C: Arm Label: Placebo (Part A); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for risankizumab | Arm Label: Risankizumab 75 mg (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Drug: placebo for risankizumab | Arm Label: Risankizumab 150 mg (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab 150 mg (Part A), Risankizumab 75 mg (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Placebo (Part A), Risankizumab 75 mg (Part A)
D: Arm Label: 80 mg Ixekizumab Auto-Injector; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab Auto-Injector | Arm Label: 80 mg Ixekizumab Prefilled Syringe; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab Prefilled Syringe | Intervention Type: DRUG; Name: Ixekizumab Auto-Injector; Assigned to Arm(s): 80 mg Ixekizumab Auto-Injector | Intervention Type: DRUG; Name: Ixekizumab Prefilled Syringe; Assigned to Arm(s): 80 mg Ixekizumab Prefilled Syringe

Answer: D